Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Arvinas and Pfizer Announce Encouraging Preliminary Phase 1b Results for Vepdegestrant Combined with Abemaciclib in Advanced ER+/HER2- Breast Cancer Quiver Quantitative, Inc. - Tue Dec 10, 6:26PM CST

Vepdegestrant combined with abemaciclib shows promising clinical activity and a favorable safety profile in advanced breast cancer patients.Quiver AI SummaryArvinas, Inc. and Pfizer Inc. announced promising...

ARVN : 18.48 (+3.65%)
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium GlobeNewswire - Tue Dec 10, 8:05AM CST

ARVN : 18.48 (+3.65%)
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference GlobeNewswire - Wed Nov 27, 6:00AM CST

ARVN : 18.48 (+3.65%)
Arvinas, Inc. to Present Clinical Data for Vepdegestrant at the 2024 San Antonio Breast Cancer Symposium Quiver Quantitative, Inc. - Tue Nov 26, 2:56AM CST

Arvinas will present three vepdegestrant posters at SABCS 2024, detailing its use in ER+/HER2- breast cancer.Quiver AI SummaryArvinas, Inc. announced the presentation of three posters detailing clinical...

ARVN : 18.48 (+3.65%)
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium GlobeNewswire - Mon Nov 25, 4:35PM CST

ARVN : 18.48 (+3.65%)
Arvinas to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Nov 4, 6:00AM CST

ARVN : 18.48 (+3.65%)
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Wed Oct 30, 6:00AM CDT

ARVN : 18.48 (+3.65%)
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day GlobeNewswire - Tue Oct 22, 3:05PM CDT

ARVN : 18.48 (+3.65%)
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 GlobeNewswire - Mon Oct 21, 6:00AM CDT

ARVN : 18.48 (+3.65%)
OSI: Fiscal Q4 Earnings Snapshot AP - Thu Aug 22, 8:16AM CDT

OSI: Fiscal Q4 Earnings Snapshot

ARVN : 18.48 (+3.65%)

Barchart Exclusives

Holiday Trading, Key Economic Data and Other Can't Miss Items This Week Barchart - 26 minutes ago
The final trading week of 2024 arrives with shortened holiday hours and potentially thin trading volumes. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot